Biogen/Eisai’s AD drug candidate, BAN2401 has shown positive results in a late-stage clinical study. This is the first late-stage anti-amyloid antibody (BAN2401) study to successfully achieve statistically significant results at 18 months. Login to read the full article.
Venclexta plus Rituxan combo reduced the risk of chronic lymphocytic leukemia (CLL) progression and death in patients by 81 percent compared to the standard-of-care regimen.
It is the first oral-based, chemotherapy-free combination which provides an option of fixed treatment duration to CLL patients.
US FDA approved Fulphila (pegfilgrastim-jmdb) – a biosimilar to Neulasta for reducing the chances of infection in patients with non-myeloid (non-bone marrow) cancer during chemotherapy. It is the first pegfilgrastim biosimilar that is approved by the US FDA.
This disease is not new in India but has revisited for the third time after previously outbreaking in the two districts of West Bengal – Siliguri and Nadia in 2001 and 2007 respectively. High fatality rate (about 70 percent) and easy person-to-person transmission of the disease had already been established during its previous encounters but still, there is no vaccine for the prevention or cure of the disease and only supportive treatment is given for the disease-related complications including neurological and respiratory complications.
Read about the most promising oncology drug candidates present in the pharmaceutical companies’ pipeline in 2018.
The potential drugs with novel mechanisms are in their late-stage of clinical development to treat diverse types of cancers.